Targeting mutated plus germline epitopes confers pre-clinical efficacy of an instantly formulated cancer nano-vaccine
Personalized cancer vaccines hold promises for future cancer therapy. Targeting neoantigens is perceived as more beneficial compared to germline, non-mutated antigens. However, it is a practical challenge to identify and vaccinate patients with neoantigens. Here we asked whether two neoantigens are...
Saved in:
Main Authors: | , , , , , , , , , , , , , , |
---|---|
Other Authors: | |
Format: | Article |
Language: | English |
Published: |
2019
|
Subjects: | |
Online Access: | https://hdl.handle.net/10356/104713 http://hdl.handle.net/10220/48630 |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Institution: | Nanyang Technological University |
Language: | English |
id |
sg-ntu-dr.10356-104713 |
---|---|
record_format |
dspace |
spelling |
sg-ntu-dr.10356-1047132023-02-28T17:04:19Z Targeting mutated plus germline epitopes confers pre-clinical efficacy of an instantly formulated cancer nano-vaccine Mohsen, Mona O. Vogel, Monique Riether, Carsten Muller, Julius Salatino, Silvia Ternette, Nicola Gomes, Ariane C. Cabral-Miranda, Gustavo El-Turabi, Aadil Ruedl, Christiane Kundig, Thomas M. Dermime, Said Knuth, Alexander Speiser, Daniel E. Bachmann, Martin F. School of Biological Sciences Molecular Genetics and Cell Biology Virus-like Particles Vaccine DRNTU::Science::Biological sciences Personalized cancer vaccines hold promises for future cancer therapy. Targeting neoantigens is perceived as more beneficial compared to germline, non-mutated antigens. However, it is a practical challenge to identify and vaccinate patients with neoantigens. Here we asked whether two neoantigens are sufficient, and whether the addition of germline antigens would enhance the therapeutic efficacy. We developed and used a personalized cancer nano-vaccine platform based on virus-like particles loaded with toll-like receptor ligands. We generated three sets of multi-target vaccines (MTV) to immunize against the aggressive B16F10 murine melanoma: one set based on germline epitopes (GL-MTV) identified by immunopeptidomics, another set based on mutated epitopes (Mutated-MTV) predicted by whole exome sequencing and a last set combines both germline and mutated epitopes (Mix-MTV). Our results demonstrate that both germline and mutated epitopes induced protection but the best therapeutic effect was achieved with the combination of both. Our platform is based on Cu-free click chemistry used for peptide-VLP coupling, thus enabling bedside production of a personalized cancer vaccine, ready for clinical translation. Published version 2019-06-11T04:47:28Z 2019-12-06T21:38:04Z 2019-06-11T04:47:28Z 2019-12-06T21:38:04Z 2019 Journal Article Mohsen, M. O., Vogel, M., Riether, C., Muller, J., Salatino, S., Ternette, N., . . . Bachmann, M. F. (2019). Targeting mutated plus germline epitopes confers pre-clinical efficacy of an instantly formulated cancer nano-vaccine. Frontiers in Immunology, 10, 1015-. doi:10.3389/fimmu.2019.01015 https://hdl.handle.net/10356/104713 http://hdl.handle.net/10220/48630 10.3389/fimmu.2019.01015 en Frontiers in Immunology © 2019 Mohsen, Vogel, Riether, Muller, Salatino, Ternette, Gomes, Cabral-Miranda, El-Turabi, Ruedl, Kundig, Dermime, Knuth, Speiser and Bachmann. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms. 14 p. application/pdf |
institution |
Nanyang Technological University |
building |
NTU Library |
continent |
Asia |
country |
Singapore Singapore |
content_provider |
NTU Library |
collection |
DR-NTU |
language |
English |
topic |
Virus-like Particles Vaccine DRNTU::Science::Biological sciences |
spellingShingle |
Virus-like Particles Vaccine DRNTU::Science::Biological sciences Mohsen, Mona O. Vogel, Monique Riether, Carsten Muller, Julius Salatino, Silvia Ternette, Nicola Gomes, Ariane C. Cabral-Miranda, Gustavo El-Turabi, Aadil Ruedl, Christiane Kundig, Thomas M. Dermime, Said Knuth, Alexander Speiser, Daniel E. Bachmann, Martin F. Targeting mutated plus germline epitopes confers pre-clinical efficacy of an instantly formulated cancer nano-vaccine |
description |
Personalized cancer vaccines hold promises for future cancer therapy. Targeting neoantigens is perceived as more beneficial compared to germline, non-mutated antigens. However, it is a practical challenge to identify and vaccinate patients with neoantigens. Here we asked whether two neoantigens are sufficient, and whether the addition of germline antigens would enhance the therapeutic efficacy. We developed and used a personalized cancer nano-vaccine platform based on virus-like particles loaded with toll-like receptor ligands. We generated three sets of multi-target vaccines (MTV) to immunize against the aggressive B16F10 murine melanoma: one set based on germline epitopes (GL-MTV) identified by immunopeptidomics, another set based on mutated epitopes (Mutated-MTV) predicted by whole exome sequencing and a last set combines both germline and mutated epitopes (Mix-MTV). Our results demonstrate that both germline and mutated epitopes induced protection but the best therapeutic effect was achieved with the combination of both. Our platform is based on Cu-free click chemistry used for peptide-VLP coupling, thus enabling bedside production of a personalized cancer vaccine, ready for clinical translation. |
author2 |
School of Biological Sciences |
author_facet |
School of Biological Sciences Mohsen, Mona O. Vogel, Monique Riether, Carsten Muller, Julius Salatino, Silvia Ternette, Nicola Gomes, Ariane C. Cabral-Miranda, Gustavo El-Turabi, Aadil Ruedl, Christiane Kundig, Thomas M. Dermime, Said Knuth, Alexander Speiser, Daniel E. Bachmann, Martin F. |
format |
Article |
author |
Mohsen, Mona O. Vogel, Monique Riether, Carsten Muller, Julius Salatino, Silvia Ternette, Nicola Gomes, Ariane C. Cabral-Miranda, Gustavo El-Turabi, Aadil Ruedl, Christiane Kundig, Thomas M. Dermime, Said Knuth, Alexander Speiser, Daniel E. Bachmann, Martin F. |
author_sort |
Mohsen, Mona O. |
title |
Targeting mutated plus germline epitopes confers pre-clinical efficacy of an instantly formulated cancer nano-vaccine |
title_short |
Targeting mutated plus germline epitopes confers pre-clinical efficacy of an instantly formulated cancer nano-vaccine |
title_full |
Targeting mutated plus germline epitopes confers pre-clinical efficacy of an instantly formulated cancer nano-vaccine |
title_fullStr |
Targeting mutated plus germline epitopes confers pre-clinical efficacy of an instantly formulated cancer nano-vaccine |
title_full_unstemmed |
Targeting mutated plus germline epitopes confers pre-clinical efficacy of an instantly formulated cancer nano-vaccine |
title_sort |
targeting mutated plus germline epitopes confers pre-clinical efficacy of an instantly formulated cancer nano-vaccine |
publishDate |
2019 |
url |
https://hdl.handle.net/10356/104713 http://hdl.handle.net/10220/48630 |
_version_ |
1759856434848202752 |